Trial Profile
A Phase IIa, Multi-Center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DNB-001 in Patients with Angina Pectoris and Moderate Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2012
Price :
$35
*
At a glance
- Drugs MSH 1001 (Primary)
- Indications Angina pectoris; Renal failure
- Focus Biomarker; Pharmacodynamics
- Sponsors Danube Pharmaceuticals
- 23 Aug 2011 New trial record